ADP-A2M4CD8

ADP-A2M4CD8 is a next-generation engineered T cell therapy developed for the treatment of solid tumors expressing the cancer-testis antigen MAGE-A4. It consists of autologous CD4+ and CD8+ T cells genetically modified to express a high-affinity T cell receptor (TCR) specific for MAGE-A4, along with an added CD8α co-receptor. The addition of the CD8α co-receptor is designed to enhance the functionality of both CD4+ and CD8+ T cells, broadening immune responses against tumor cells by enabling helper (CD4+) T cells to acquire cytotoxic activity while retaining their helper function. The therapy is administered intravenously following lymphodepleting chemotherapy. Clinical trials have shown encouraging anti-tumor activity in multiple advanced solid tumor types, including ovarian cancer, urothelial carcinoma, head & neck cancers, esophageal cancer, gastric cancer, and others in HLA A*02–positive patients whose tumors express MAGE-A4[1][2][3][6].

Other names

ADP-A2M4CD8ADP-A-2M4CD8ADP-A 2M4CD8SPEAR T-cell therapy (ADP-A2M4CD8)